Proliferative Diabetic Retinopathy (PDR) Drug Pipeline Analysis and Therapeutic Assessment for H2 2017

Market Research HUB

Albany, New York, September 28, 2017: All diabetic patients are at risk of developing eye diseases is called diabetic retinopathy. The longer the patient has diabetes and the more uncontrolled it is, the greater the risk. Proliferative diabetic retinopathy is an advanced form of diabetic eye disease. In recent years, growing incidence and prevalence of diabetes, growing cases of diabetes-associated blindness, rising geriatric population across the world has positively impacted the Proliferative Diabetic Retinopathy therapeutics market. To elaborate further about the effective treatments and clinical trials of PDR, a new pipeline study titled “Proliferative Diabetic Retinopathy (PDR) – Pipeline Review, H2 2017” has been broadcasted to the wide repository of Market Research Hub (MRH). This study provides broad information on the therapeutics under development for proliferative diabetic retinopathy, with the complete analysis by stage of development, drug target, route of administration (RoA), mechanism of action (MoA) and molecule type.

Request free Sample Report:

Proliferative Diabetic Retinopathy (PDR) is the advanced stage of diabetic retinopathy characterized by abnormal growth of blood vessel, which results in swelling of retina called Diabetic Macular Edema (DME). There are several treatments for proliferative diabetic retinopathy has evolved over the last decades. In this study, the readers will get to know about the brief overview of proliferative diabetic retinopathy along with its therapeutic development. In addition, the therapeutic development for the disease has been reviewed on the basis of clinical trials methods and major companies’ efforts involved in it along with their dormant and discontinued projects.  Because of the large number and permutations of specific drugs that have been evaluated in trials, critical analysis of combinations is challenging.

It has been analyzed that proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. Its symptoms include spots or dark strings floating in vision, blurred vision, vision loss, fluctuating vision, and difficulty with color perception. A laser procedure called panretinal photocoagulation is the main treatment for proliferative diabetic retinopathy. Ophthalmologists have now several novel drugs including anti-VEGF drugs and steroid implants available in their armamentarium for treating patients with DME and PDR. Many more drugs are in the pipeline in different phases of clinical trials. Drugs profiled in this study are AR-13154, cyclosporine, emixustat hydrochloride, atesidorsen sodium, PAN-90806, ocriplasmin, squalamine lactate and THR-687.

Browse Full Report With TOC:

Later, the study reviews the key players involved in therapeutic development for this severe type of diabetic retinopathy; and also features dormant and discontinued projects. Key players include Antisense Therapeutics Ltd., Ohr Pharmaceutical Inc., Aerie Pharmaceuticals Inc., Acucela Inc., ThromboGenics NV, Icon Bioscience Inc., Ribomic Inc., and PanOptica Inc. The guide also helps in identifying emerging players in the market along with their portfolios which enhance decision-making capabilities for the new entrants.

Enquire About this Report:

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of reports and analysis. MRH’s expansive collection of  Pharmaceutical industry market reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)



Read Industry News at –







Designed by
Powered by
%d bloggers like this: